In fact, a preclinical study demonstrated that the second-generation EGFR-TKI afatinib uniquely decreased EGFR activation, as well as that of HER2, HER3, HER4, and their downstream Akt phosphorylation, in heregulin-expressing cancer cells, overcoming heregulin-mediated resistance28. This evidence concerns the gene ERBB2 and cancer.